G Richard Curl, MD
Vascular Surgery · Buffalo, NYNPI 1144287160
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Endologix LLC accounts for 82.7% of it on its own, with 30 other manufacturers making up the rest.
Across 420 payments — averaging $173.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Endologix LLC$60K
- Inari Medical, Inc.$5K
- Boston Scientific$2K
- Shape Memory Medical Inc.$937
- Medtronic$861
- W. L. Gore & Associates, Inc.$848
- plus $3K from 25 others
Across 6 payments — averaging $1762.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Endologix LLC$11K
What the payments were for
- Consulting fees$42,70059%
- Travel & lodging$6,8279%
- Food & beverage$23,38032%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Endologix LLC | 165 | $60,299 |
| Inari Medical, Inc. | 50 | $4,658 |
| Boston Scientific | 45 | $2,449 |
| Shape Memory Medical Inc. | 11 | $937 |
| Medtronic(2 entities) | 27 | $861 |
| W. L. Gore & Associates, Inc. | 25 | $848 |
| Silk Road Medical, Inc. | 10 | $502 |
| AOP Health US, LLC | 1 | $450 |
| Johnson & Johnson | 18 | $284 |
| Cook Medical LLC | 2 | $176 |
| Bard Peripheral Vascular, Inc. | 11 | $171 |
| Smith+Nephew | 12 | $171 |
| Bolton Medical Inc | 7 | $163 |
| Lemaitre Vascular, Inc. | 4 | $155 |
| Sanara Medtech Inc. | 1 | $143 |
| Philips North America LLC | 7 | $109 |
| Pfizer | 5 | $92 |
| Integra Lifesciences Corporation | 2 | $67 |
| Terumo Medical Corporation | 3 | $54 |
| Stryker | 1 | $53 |
| EKOS Corporation | 1 | $46 |
| Organogenesis Inc. | 3 | $43 |
| KCI USA, Inc. | 1 | $36 |
| Cardiovascular Systems Inc. | 1 | $28 |
| Okami Medical, Inc. | 1 | $23 |
| Imperative Care, Inc | 1 | $21 |
| Siemens Medical Solutions USA, Inc. | 1 | $17 |
| Teleflex LLC | 1 | $16 |
| Convatec Inc. | 1 | $14 |
| Penumbra, Inc. | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Alto Abdominal Stent Graft System$27,881
- Ovation$25,212
- ENDOCROSS Device$2,609
- Torus Stent Graft System$2,609
- FLOWTRIEVER CATHETER, S$1,979
- CT THROMBECTOMY SYSTEM KIT$1,761
- FlowTriever$1,711
- ClotTriever$1,711
- GENERAL - THERAPIES$1,214
- Rapiblyk$900
- IMPEDE EMBOLIZATION PLUG$687
- AFX2 Bifurcated Endograft System$490
- ENROUTE Transcarotid Stent$285
- ENROUTE Transcarotid Neuroprotection System$285
- GORE VIABAHN VBX Balloon Expandable Endo$168
- Zenith Alpha$149
- ENHANCE Transcarotid Peripheral Access Kit$148
- ENROUTE .014 Guidewire$148
- GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis$143
- CellerateRx$143
How this compares
$72,907 in reported general payments places this provider in the 85th percentile of 405 vascular surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 134 | $123,718 |
| XareltoRivaroxaban | 75 | $61,932 |
| ClopidogrelClopidogrel Bisulfate | 391 | $5,254 |
| Cilostazol | 64 | $1,050 |
| Gabapentin | 34 | $592 |
| Oxycodone Hcl | 18 | $62 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $92 | $123,718134 claims |
| Johnson & JohnsonXarelto | $284 | $61,93275 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 405 vascular surgery providers in New York.
Other vascular surgery in Buffalo
- Sonya NoorBuffalo$991K
- Gary GelbfishNew York$1.9M
- Sundaram RavikumarDobbs Ferry$1.8M
- Antonios GasparisHuntington$1.5M
- John LantisNew York$922K
- Brian DerubertisNew York$714K
- James McKinseyNew York$616K
- Peter FariesNew York$494K
- Robert RheeBrooklyn$338K
- Ajit RaoNew York$294K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.